BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $EIKN readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06246110-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~EIK1001 readout (P2) · Eikon Therapeutics $EIKN
DESCRIPTION:A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chem
 otherapy in Patients With Stage 4 NSCLC\n\nPrimary completion date: 2026-1
 2 (estimated) — month only\, shown on the 1st\nPhase 2 · Oncology · NS
 CLC\nEnrollment: 70 · Sites: 38\n\nPrimary completion = last participant'
 s primary-endpoint data collected\; topline results usually follow weeks t
 o months later. Sponsor-reported\, often an estimate. Not investment advic
 e.\n\nhttps://datacutoff.com/radar.html?nct=NCT06246110\nhttps://clinicalt
 rials.gov/study/NCT06246110
URL:https://datacutoff.com/radar.html?nct=NCT06246110
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
